Cyrus Taraporevala Adds to Pfizer Inc. Holdings with Recent Purchase

Cyrus Taraporevala recently bought 1,544 shares of Pfizer Inc. (NYSE:PFE) on June 26, 2026. The shares were purchased at an average price of $24.29, totaling approximately $37,503.76.

Insider Buying and Selling at Pfizer Inc.

On June 26, 2026, several insiders made purchases of Pfizer Inc. stock. Cyrus Taraporevala acquired 1,544 shares at $24.29 each. Other insiders, including James Quincey, Joseph Echevarria, Shantanu Narayen, Mortimer Buckley, and James Smith, also purchased shares on the same day, each buying between 1,544 and 2,059 shares at the same price.

Other Institutional Activity in Pfizer Inc.

Several major funds have been active with Pfizer Inc. stock. BlackRock, Inc. increased its holdings by 5,195,022 shares, bringing its total to 498,257,550 shares valued at about $13.99 billion, marking a 1.1% increase. Vanguard Capital Management LLC opened a new position with 369,430,012 shares worth approximately $10.37 billion. State Street Corp added 1,144,701 shares, ending with 301,589,865 shares valued at $8.47 billion, reflecting a 0.4% increase. Geode Capital Management, LLC increased its stake by 3,369,661 shares to a total of 133,561,742 shares, valued at roughly $3.74 billion, representing a 2.6% increase. Fisher Asset Management, LLC significantly boosted its holdings by 53,012,321 shares, now holding 104,964,427 shares valued at $2.95 billion, a 102% increase.

Pfizer Inc. Stock Down 14.4%

Shares of Pfizer Inc. (NYSE:PFE) traded near $24.37 on Wednesday. The company has a market cap of $138.44 billion, with a P/E ratio of 18.54 and a forward P/E of 8.59. Pfizer's stock has a 52-week low of $23.11 and a high of $28.75. The 50-day moving average is $25.97, and the 200-day moving average is $25.87. The company maintains a current ratio of 1.25 and a quick ratio of 0.85, with a debt-to-equity ratio of 71.60.

Recent Earnings

Pfizer reported a revenue of $63.32 billion with a growth rate of 5.4%. The company's earnings per share (EPS) is $1.31, with a net margin of 11.83% and a return on equity (ROE) of 8.31%. Pfizer is expected to announce its next earnings on August 4, 2026.

Dividend

Pfizer Inc. offers an annual dividend rate of $1.72, yielding 7.08%. The dividend payout ratio is 131.3%.

Analysts Set New Price Targets

On April 29, 2026, Citigroup maintained a hold rating on Pfizer with a $27.00 price target. CICC initiated coverage with a buy rating and a $33.00 target on April 16, 2026. UBS and Morgan Stanley both maintained hold ratings with $27.00 and $28.00 targets, respectively, in April 2026. B of A Securities kept a hold rating with a $26.00 target on April 9, 2026. Guggenheim maintained a buy rating with a $36.00 target on March 24, 2026. HSBC also maintained a buy rating with a $32.00 target on March 17, 2026. Argus Research upgraded the stock to a buy with a $35.00 target on March 2, 2026. The consensus recommendation is a buy, with a mean target price of $29.15 based on 27 analyst opinions.

About Pfizer Inc.

Pfizer Inc., headquartered in New York, NY, is a leading biopharmaceutical company involved in the discovery, development, manufacture, and marketing of healthcare products globally. With three main segments—Biopharma, PC1, and Pfizer Ignite—the company offers a wide range of products, including medications for cardiovascular, metabolic, and rare diseases, as well as vaccines and oncology treatments. Dr. Albert Bourla leads the company as CEO, overseeing approximately 75,000 employees worldwide.

Bottom Line

Cyrus Taraporevala's recent purchase of Pfizer shares adds to the broader insider activity at the company. Investors often watch such moves for potential signals about the company's future. However, it's important to remember that this insider data reflects past actions and may not indicate current positions.